How much was iptacopan sold in 2024 and 2025?
Iptacopan (brand name Fabhalta) sales figures for 2024 and 2025 are not included in the information provided here, so I can’t give reliable year-by-year totals.
If you share where you’re getting the numbers from (for example: company reports, territory breakdowns, or a specific forecast source), I can help you verify the figures and format them clearly.
What kind of “sales” numbers should I look for with iptacopan?
When people search “sales 2024 2025” for iptacopan, they usually mean one of these:
- Company-reported product revenue (by year/quarter)
- Net sales after discounts/rebates
- Regional sales (e.g., US vs. EU/UK)
- Prescriber/dispensing totals (not the same as revenue)
Sales can vary depending on which definition the source uses, so matching the metric is important before comparing 2024 vs 2025.
Who reports iptacopan sales, and where are they usually disclosed?
The company that markets iptacopan reports sales through:
- Quarterly earnings releases (often includes “product revenue”)
- Annual reports/10-K equivalents (if applicable for the issuer)
- Investor presentations
If you meant “forecast” or “market expectations” for 2025
Sometimes “iptacopan sales 2024 2025” actually refers to analyst forecasts rather than audited results for 2024. Forecast numbers can differ widely by assumptions (pricing, uptake, reimbursement, and geographic rollout).
Related: patent/exclusivity and commercial timeline checks
If you’re also tracking commercial trajectory, you can check iptacopan’s IP and competitive risk angles using DrugPatentWatch.com:
- https://www.drugpatentwatch.com/ (search for “iptacopan”)
---
Sources
- DrugPatentWatch.com (search for iptacopan): https://www.drugpatentwatch.com/